Shire PLC (NASDAQ:SHPG)‘s stock had its “buy” rating reissued by research analysts at Jefferies Group in a research report issued to clients and investors on Tuesday. They presently have a $262.00 price objective on the biopharmaceutical company’s stock. Jefferies Group’s price target points to a potential upside of 28.43% from the company’s previous close.

Other equities research analysts have also recently issued research reports about the company. Sanford C. Bernstein reissued an “outperform” rating and set a $222.00 target price on shares of Shire PLC in a report on Thursday, June 9th. Royal Bank Of Canada reissued an “outperform” rating on shares of Shire PLC in a report on Wednesday, June 15th. BTIG Research reissued a “buy” rating and set a $230.00 target price on shares of Shire PLC in a report on Tuesday, July 12th. RBC Capital Markets reissued an “outperform” rating on shares of Shire PLC in a report on Wednesday, August 3rd. Finally, Shore Capital reissued a “buy” rating on shares of Shire PLC in a report on Tuesday, July 26th. Four equities research analysts have rated the stock with a hold rating and twenty-three have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $230.67.

Shares of Shire PLC (NASDAQ:SHPG) opened at 204.00 on Tuesday. The stock’s 50 day moving average price is $196.07 and its 200 day moving average price is $183.99. The firm has a market cap of $60.76 billion, a PE ratio of 42.39 and a beta of 1.11. Shire PLC has a 12-month low of $147.60 and a 12-month high of $231.32.

Shire PLC (NASDAQ:SHPG) last issued its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $3.38 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.03 by $0.35. The business earned $2.43 million during the quarter, compared to the consensus estimate of $2.28 billion. Shire PLC had a return on equity of 17.70% and a net margin of 13.19%. The business’s revenue was up 55.9% on a year-over-year basis. During the same period in the previous year, the firm posted $2.63 earnings per share. On average, equities research analysts predict that Shire PLC will post $12.93 EPS for the current fiscal year.

The firm also recently disclosed a dividend, which will be paid on Friday, October 7th. Investors of record on Friday, September 9th will be issued a $0.139 dividend. The ex-dividend date is Wednesday, September 7th. Shire PLC’s dividend payout ratio is presently 15.63%.

A number of large investors have recently modified their holdings of SHPG. Pioneer Investment Management Inc. boosted its stake in shares of Shire PLC by 30.6% in the fourth quarter. Pioneer Investment Management Inc. now owns 15,699 shares of the biopharmaceutical company’s stock worth $3,218,000 after buying an additional 3,680 shares in the last quarter. Norges Bank acquired a new stake in shares of Shire PLC during the fourth quarter worth about $31,671,000. Fisher Asset Management LLC boosted its stake in shares of Shire PLC by 16.8% in the first quarter. Fisher Asset Management LLC now owns 39,657 shares of the biopharmaceutical company’s stock worth $7,206,000 after buying an additional 5,703 shares in the last quarter. Raymond James Trust N.A. boosted its stake in shares of Shire PLC by 4.6% in the first quarter. Raymond James Trust N.A. now owns 2,591 shares of the biopharmaceutical company’s stock worth $445,000 after buying an additional 114 shares in the last quarter. Finally, Quantitative Systematic Strategies LLC boosted its stake in shares of Shire PLC by 225.0% in the first quarter. Quantitative Systematic Strategies LLC now owns 4,758 shares of the biopharmaceutical company’s stock worth $802,000 after buying an additional 3,294 shares in the last quarter. Hedge funds and other institutional investors own 24.26% of the company’s stock.

About Shire PLC

Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.

5 Day Chart for NASDAQ:SHPG

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.